ASCOT: The Australasian COVID-19 Trial

Australasian COVID-19 Trial

ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

Trial Overview

29 patients enrolled in trial

29 patients randomised

27 sites activated

News

Convalescent plasma for COVID-19
September 10, 2020
Convalescent plasma is a treatment arm in ASCOT. Participants are randomised (like the flip of a coin) to either receiving convalescent plasma or the usual best standard of care without convalescent plasma.
- Read more
AustralaSian COVID-19 Trial (ASCOT) removes hydroxychloroquine and lopinavir/ritonavir arms of the trial
July 30, 2020
Following reports that that hydroxychloroquine and lopinavir/ritonavir are not effective in reducing mortality from COVID-19, the AustralaSian COVID-19 Trial (ASCOT) Steering Committee has also made the decision to remove the hydroxychloroquine and lopinavir/ritonavir arms of the Trial.
- Read more
Convalescent plasma treatment for COVID-19 introduced to ASCOT and REMAP-CAP trials
July 30, 2020

Convalescent plasma has been introduced to the AustralaSian COVID-19 Trial (ASCOT) and Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) clinical trials in a bid to identify the best strategy to treat patients hospitalised with COVID-19.
- Read more